
    
      A Phase III, Multicenter, Randomized Study of ABX Plus Cisplatin (AP) Versus Gemcitabine Plus
      Cisplatin (GP) as First-Line Treatment in Patients With Advanced Triple-Negative Breast
      Cancer
    
  